Our good friend Raman Minhas at ATPBio has a really good post today on the critical factors for a medtech company to be successful using a virtual organizational model. Raman's…
As with BIO 2011, the bulk of our time was spent in the One-on-One Partnering sessions. More general reviews are found here, here, and here. As usual, BIO put on…
While we were all burning shoe leather at BIO2012 this week, the good folks at eMarketer published an interesting article on digital marketing by pharma: Digital advertising spending by the…
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
In researching our latest project, we came across some startling statistics. A report published by the Crohn's and Colotis Foundation of Canada noted: This landmark document revealed that over 200,000…
So said Shams Ruston from Labopharm at last week's Interphex conference in New York. We happen to agree. In fact, there are two ways to look at this. From the…
Yesterday, we responded on LinkedIn to the following note: THis is our first BIO conference in June and want to make it a great one. Any hints or helpful suggestions…
AOL sells patents to Microsoft. Why? The reasons for AOL selling these patents are pretty clear: Shares of AOL surged as much as 45% Monday, hitting their highest point in…
The past seven days have brought us two very interesting transactions. First, on March 14, Lyon-based Flamel announced their acquisition of St. Louis-based Eclat Pharmaceuticals. The press release contains a…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…